Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C

Antiviral Therapy

Volumn 17, Issue 6 PART B, 2012, Pages 1189-1199

  Gellad, Ziad F ^a,b   Reed, Shelby D ^a   Muir, Andrew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HISTORY OF MEDICINE; HUMAN; MEDICAL DECISION MAKING; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; UNCERTAINTY;

ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; EUROPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MODELS, ECONOMIC; OLIGOPEPTIDES; PROLINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84867265787     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2430     Document Type: Review

References (97)

1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
3. Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am 2011; 40:481-494.
4. Sharma P, Lok AS. Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology 2011; 141:1963-1967.
5. Porter ME. What is value in health care? N Engl J Med 2010; 363:2477-2481.
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
7. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-827.e1.
8. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-129.e18.
9. World Health Organization. Hepatitis C Fact Sheet #164. (Updated 22 March 2012. Accessed 30 November 2011.) Available from apps.who.int/inf-fs/en/ fact164.html
10. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-29.
11. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14:1-21.
12. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31:61-80.
13. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714. (Pubitemid 46780630)
14. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011; 45:e17-e24.
15. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9:34.
16. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
17. Kershenobich D, Razavi HA, Cooper CL, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31:4-17.
18. United States Bureau of Labor Statistics. Inflation Calculator CPI. (Accessed 15 November 2011.) Available from www.bls.gov/data/inflation- calculator.htm
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press 1996.
20. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1172-1177. (Pubitemid 26329746)
21. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1339-1341. (Pubitemid 26346934)
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1253-1258. (Pubitemid 26337709)
23. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: The ISPOR Drug Cost Task Force Report - Part II. Value Health 2010; 13:8-13.
24. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year. Med Decis Making 2000; 20:332-342. (Pubitemid 30479101)
25. Shiroiwa T, Sung Y-K, Fukuda T, Lang H-C, Bae S-C, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19:422-437.
26. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163:1637-1641. (Pubitemid 36898950)
27. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In Gold MR, Siegel JE, Russell LB, Weinstein MC (Editors). Cost-effectiveness in health and medicine. New York: Oxford University Press 1996; pp. 176-213.
28. Mycka JM, Dellamano R, Kolassa EM, et al. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: The ISPOR Drug Cost Task Force Report-Part V. Value Health 2010; 13:25-27.
29. Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: The ISPOR Drug Cost Task Force Report-Part I. Value Health 2010; 13:3-7.
30. Mansley EC, Carroll NV, Chen KS, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report-Part III. Value Health 2010; 13:14-17.
31. Shi L, Hodges M, Drummond M, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: The ISPOR Drug Cost Task Force Report-Part VI. Value Health 2010; 13:28-33.
32. Mullins CD, Seal B, Seoane-Vazquez E, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US Government payers perspectives: The ISPOR Drug Cost Task Force Report-Part IV. Value Health 2010; 13:18-24.
33. Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (NY) 2011; 7:154-162.
34. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009; 12 Suppl 1:S5-S9.
35. World Health Organization (WHO). Global Burden of Disease Metrics. (Updated 22 March 2012. Accessed 30 November 2011.) Available from http://www.who.int/healthinfo/global-burden-disease/metrics-daly/en/
36. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008; 28:582-592. (Pubitemid 351989999)
37. Thein H-H, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100:643-651. (Pubitemid 40487565)
38. Chong CAKY, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-638. (Pubitemid 36348537)
39. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health 2009; 12 Suppl 1:S10-S15.
40. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 2009; 360:816-823.
41. Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models. Med Decis Making 2011; 31:675-692.
42. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5:157-177. (Pubitemid 16130640)
43. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9:923-930.
44. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001; 34:748-755. (Pubitemid 32488791)
45. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-a is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45:579-587. (Pubitemid 46453759)
46. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46:206-212. (Pubitemid 44959155)
47. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-288.e1.
48. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-516.e1.
49. Morgan TR, Ghany MG, Kim H-Y, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-844.
50. Neal KR. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56:1098-1104. (Pubitemid 47123240)
51. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38:493-502. (Pubitemid 36919871)
52. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123:483-491. (Pubitemid 34827193)
53. Cardoso A-C, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52:652-657.
54. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 2005; 3 Suppl 2:S141-S143. (Pubitemid 41427747)
55. Innes HA, Hutchinson SJ, Allen S, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011; 54:1547-1558.
56. Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167:743-750. (Pubitemid 351430942)
57. Grebely J, Raffa JD, Lai C, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011; 18:32-41.
58. Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59:1135-1140.
59. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.e6.
60. Kim WR, Poterucha JJ, Benson JT, Therneau TM. The impact of competing risks on the observed rate of chronic hepatitis C progression. Gastroenterology 2004; 127:749-755. (Pubitemid 39208408)
61. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88:240-243. (Pubitemid 23053477)
62. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-832. (Pubitemid 27129209)
63. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34:809-816. (Pubitemid 32928008)
64. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 Suppl 5B:S35-S46. (Pubitemid 35253462)
65. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97-104. (Pubitemid 36055343)
66. Ryder SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53:451-455. (Pubitemid 38241346)
67. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43:1303-1310. (Pubitemid 43980109)
68. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trépo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 2007; 27:335-339. (Pubitemid 46416623)
69. Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54:396-405.
70. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-431.
71. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
72. Verma S, Wang C-H, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-270. (Pubitemid 43054201)
73. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang L-Y, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63. (Pubitemid 41623269)
74. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134:1699-1714. (Pubitemid 351615412)
75. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 2012; 156:263-270.
76. Sweeting MJ, Farewell VT, De Angelis D. Multi-state Markov models for disease progression in the presence of informative examination times: an application to hepatitis C. Stat Med 2010; 29:1161-1174.
77. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22:1863-1873.
78. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-865.
79. Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-a therapy for chronic hepatitis C. Ann Intern Med 1997; 127:866-874.
80. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17:687-694. (Pubitemid 36418893)
81. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50:253-258. (Pubitemid 34087941)
82. Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon [alpha]-2a and ribavirin compared with interferon [alpha]-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99:1490-1496. (Pubitemid 39180097)
83. Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon [alpha]-2a plus ribavirin versus interferon [alpha]-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22:257-265. (Pubitemid 38393394)
84. Wong JB, Poynard T, Ling M-H, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon [alpha]-2b alone or with ribavirin as initial treatment of chronic hepatitis c. Am J Gastroenterol 2000; 95:1524-1530. (Pubitemid 30396314)
85. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432. (Pubitemid 36250066)
86. Yeh W-S, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the veterans affairs health care system. Pharmacotherapy 2007; 27:813-824. (Pubitemid 46849425)
87. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98:2354-2362. (Pubitemid 37448742)
88. Buti M, Casado MA, Esteban R. Evaluating the cost of sustained virologic response in naive chronic hepatitis C patients treated à la carte. Aliment Pharmacol Ther 2007; 26:705-716. (Pubitemid 47246206)
89. Nakamura J, Kobayashi K, Toyabe S, Aoyagi Y, Akazawa K. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol Hepatol 2007; 19:733-739. (Pubitemid 47266700)
90. Gellad ZF, Reed SD, Muir AJ, et al. Truncated therapy based on rapid virologic response is a cost effective treatment paradigm for chronic hepatitis C. Gastroenterology 2011; 140:S-895.
91. Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response. Pharmacoeconomics 2009; 27:341-354.
92. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C. Ann Intern Med 2012; 156:279-290.
93. Chhatwa IJ, Ferrante SA, Dasbach EJ, Khoury AE, Brass CA, Burroughs M. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. Hepatology 2011; 54:801A.
94. Ferrante SA, Chhatwa IJ, Elbasha E, et al. Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1. Hepatology 2011; 54:795A.
95. Gellad ZF, Naggie S, Reed SD, et al. The cost-effectiveness of a telaprevir inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the CC IL-28B polymorphism. Hepatology 2011; 54:417A.
96. Red Book. New Jersey: Thomson Reuters 2010.
97. United States Department of Veterans Affairs. Drug Pharmaceutical Prices. (Accessed 28 September 2011.) Available from http://www.pbm.va.gov/ DrugPharmaceuticalPrices.aspx